STOCK TITAN

Savara Inc. - $SVRA STOCK NEWS

Welcome to our dedicated page for Savara news (Ticker: $SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Savara's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Savara's position in the market.

Rhea-AI Summary
Savara Inc. (SVRA) reports financial results for Q3 2023, remains on track to release top line data from the pivotal Phase 3 IMPALA-2 trial by 2Q 2024. The company also plans to launch an aPAP antibody blood test and disease awareness campaign by the end of the year. With approximately $168M in cash, Savara has a strong balance sheet and believes it is capitalized into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
-
Rhea-AI Summary
Savara Inc. (SVRA) to Participate in Fireside Chat at Jefferies London Healthcare Conference on November 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
conferences
-
Rhea-AI Summary
Savara Inc. grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Savara Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary
Savara Inc. grants inducement awards to three new employees, consisting of options to purchase 150,000 shares of the Company's common stock. The options have an exercise price of $3.57 per share and vest quarterly over a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Savara Inc. has priced an underwritten offering of 21,000,000 shares of common stock at $3.00 per share, along with 5,666,667 pre-funded warrants at $2.999 per warrant. The offering is expected to generate approximately $80 million in gross proceeds. New and existing investors are participating in the offering, and it is set to close on July 17, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
Savara Inc.

Nasdaq:SVRA

SVRA Rankings

SVRA Stock Data

650.12M
74.01M
6.17%
86.56%
2.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About SVRA

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com